AKR1C1
MOLECULAR TARGETaldo-keto reductase family 1 member C1
AKR1C1 (aldo-keto reductase family 1 member C1) is targeted by 7 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting AKR1C1
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | flurbiprofen | 4.33 | 75 |
| 2 | caffeic acid phenethyl ester | 4.25 | 69 |
| 3 | flufenamic acid | 4.14 | 62 |
| 4 | benzbromarone | 4.13 | 61 |
| 5 | mefenamic acid | 3.93 | 50 |
| 6 | meclofenamic acid | 3.50 | 32 |
| 7 | Medroxyprogesterone Acetate | 1.10 | 2 |
About AKR1C1 as a Drug Target
AKR1C1 (aldo-keto reductase family 1 member C1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 7 compounds with documented AKR1C1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
AKR1C1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.